Pelvic Inflammatory Disease — ED Treatment

Key Points

• PID is a clinical diagnosis with intentionally sensitive treatment criteria because missed infection can cause permanent tubal damage.
• Cervical motion, uterine, or adnexal tenderness in an at-risk patient with pelvic pain and no better diagnosis is enough to justify empiric treatment.
• Negative gonorrhea or chlamydia testing does not exclude PID because upper-tract disease may be polymicrobial.
• Outpatient CDC therapy includes ceftriaxone plus 14 days of doxycycline and metronidazole for most mild to moderate cases.
• Pregnancy, tubo-ovarian abscess, severe illness, inability to tolerate oral therapy, or inability to exclude a surgical emergency favors admission.
• Failure to improve within about 72 hours requires diagnostic and treatment reassessment.
• Sexual partners require evaluation and treatment to prevent reinfection.
• Long-term complications include infertility, ectopic pregnancy, chronic pelvic pain, and recurrent PID.

Algorithm

1. Assess hemodynamic stability, pregnancy status, pain severity, fever, vomiting, and peritoneal signs.
2. Perform pelvic examination and look for cervical motion, uterine, or adnexal tenderness and mucopurulent discharge.
3. Obtain pregnancy testing and gonorrhea/chlamydia NAAT; add HIV and syphilis testing and other STI testing as indicated.
4. Use pelvic ultrasound when abscess, torsion, ectopic pregnancy, or other structural disease is a concern.
5. If PID criteria are met and no better diagnosis is identified, start empiric antibiotics without waiting for test results.
6. Determine whether outpatient treatment is safe or whether pregnancy, severe illness, abscess, vomiting, surgical uncertainty, or follow-up concerns require admission.
7. Reassess within 48 to 72 hours; lack of improvement should trigger imaging, alternate diagnosis review, and possible drainage or surgery.
8. Treat partners, counsel abstinence until treatment completion and symptom resolution, and arrange repeat STI testing when indicated.

Clinical Synopsis & Reasoning

Pelvic inflammatory disease is a clinical syndrome encompassing infection and inflammation of the endometrium, fallopian tubes, ovaries, and adjacent pelvic structures. Neisseria gonorrhoeae and Chlamydia trachomatis are important causes, but many cases are polymicrobial and involve anaerobes and organisms associated with the vaginal microbiome. Mycoplasma genitalium can also be associated with PID. The long-term consequence of missed or delayed treatment is tubal injury, which can lead to infertility, ectopic pregnancy, recurrent PID, and chronic pelvic pain even after the acute infection resolves.

The presentation is variable. Patients may report bilateral or diffuse lower abdominal pain, dyspareunia, abnormal vaginal discharge, postcoital or intermenstrual bleeding, dysuria, fever, nausea, or pain that worsens with movement. Some have only mild symptoms. The CDC recommends a deliberately low threshold for empiric treatment because no single historical, physical, or laboratory finding is sufficiently sensitive. In a sexually active patient at risk for an STI who has pelvic or lower abdominal pain, empiric therapy is appropriate when no other cause is identified and at least one minimum examination criterion is present: cervical motion tenderness, uterine tenderness, or adnexal tenderness.

Pregnancy testing is essential because ectopic pregnancy can mimic PID and changes both disposition and antibiotic selection. Tubo-ovarian abscess, appendicitis, ovarian torsion, ruptured cyst, pyelonephritis, nephrolithiasis, endometriosis, and other surgical or gynecologic emergencies should be considered. Vaginal or cervical nucleic acid amplification testing for gonorrhea and chlamydia should be obtained, but negative testing does not exclude upper-tract infection. Pelvic ultrasound is most useful when abscess, torsion, ectopic pregnancy, or another structural process is suspected rather than as a mandatory test in every uncomplicated PID presentation.

Treatment Strategy & Disposition

Treat as soon as the clinical threshold is met. For outpatient treatment of mild to moderate PID, the CDC regimen is ceftriaxone 500 mg IM once for patients weighing less than 150 kg, plus doxycycline 100 mg orally twice daily for 14 days, plus metronidazole 500 mg orally twice daily for 14 days. Patients weighing at least 150 kg with documented gonococcal infection should receive ceftriaxone 1 g. Metronidazole improves anaerobic coverage and also treats bacterial vaginosis, which commonly accompanies PID.

Hospitalization is appropriate for pregnancy, severe clinical illness, high fever, nausea or vomiting that prevents oral therapy, tubo-ovarian abscess, inability to exclude a surgical emergency, failure of outpatient treatment, or concern that the patient will not be able to complete therapy. Parenteral options include ceftriaxone plus doxycycline plus metronidazole, or other CDC-supported regimens. For tubo-ovarian abscess, broad anaerobic coverage is important and inpatient observation is generally recommended. Failure to improve within about 72 hours should prompt reassessment of the diagnosis, imaging, adherence, resistance, abscess drainage needs, or surgical pathology.

Patients should abstain from sexual intercourse until therapy is complete, symptoms have resolved, and partners have been evaluated and treated. Sex partners during the preceding 60 days should be evaluated, tested, and presumptively treated for gonorrhea and chlamydia as appropriate. Test for HIV and syphilis in all patients diagnosed with PID. For gonococcal or chlamydial PID, repeat testing about 3 months after treatment is recommended because reinfection is common. An intrauterine device usually does not need to be removed immediately; close follow-up is required, and removal can be considered if improvement does not occur after 48 to 72 hours of treatment.

Epidemiology / Risk Factors

• PID most often affects sexually active adolescents and reproductive-age adults.
• Prior PID, new or multiple sexual partners, and untreated gonorrhea or chlamydia increase risk.
• Many cases are polymicrobial rather than attributable to a single STI pathogen.
• Repeated episodes increase cumulative risk of tubal infertility and ectopic pregnancy.

Investigations

Example Regimens

Pharmacology

Prognosis / Complications

• Most uncomplicated cases improve with prompt appropriate antibiotics.
• Delay in treatment increases the likelihood of tubal scarring and reproductive complications.
• Tubo-ovarian abscess may require prolonged antibiotics, drainage, or surgery.
• Reinfection is common when partners are not treated or when follow-up testing is missed.
• Chronic pelvic pain can persist even after microbiologic cure because of inflammatory and adhesive sequelae.

Patient Education / Counseling

• Complete the entire antibiotic course even if pain improves rapidly.
• Avoid sexual intercourse until treatment is complete, symptoms have resolved, and partners have been treated.
• Explain that partners from the prior 60 days need evaluation for gonorrhea and chlamydia.
• Return urgently for worsening pain, fainting, persistent vomiting, high fever, pregnancy-related symptoms, or new peritoneal pain.
• Use condoms consistently to reduce recurrent STI exposure.
• Arrange repeat testing for gonorrhea or chlamydia about 3 months after treatment when those infections are diagnosed.

Notes

PID management deliberately accepts some overtreatment in exchange for reducing missed disease. The reproductive consequences of delayed treatment can be substantial, while the bedside diagnosis is imperfect. This is why a patient does not need fever, leukocytosis, a positive NAAT, or abnormal ultrasound before antibiotics are started when the minimum clinical criteria and risk context are present.

The ED disposition decision is not based only on pain severity. Pregnancy, inability to tolerate oral therapy, concern for abscess, surgical diagnostic uncertainty, or unreliable follow-up can each justify inpatient care. A patient discharged on oral therapy needs a concrete 48-to-72-hour reassessment plan, not simply a recommendation to return if worse.

References

1. CDC STI Treatment Guidelines: Pelvic Inflammatory Disease — Link